Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation

Table 2

Pharmacokinetic data.

Patient	Nilotinib csf concentration [ng/mL], (range)	Nilotinib plasma concentration [ng/mL], (range)	Nilotinib csf/plasma ratio [%], (range)	Csf protein concentration [g/L]	Plasma protein concentration [g/L]	Free nilotinib in plasma concentration [ng/mL]*	Nilotinib csf concentration/free nilotinib plasma concentration [%,]*
1	4 (3.6–15)	1640 (1544–1736)	0.26 (0.23–0.84)	0.49 (0.31–0.75)	76 (69–77)	32.8	12
2	13 (4–18)	955 (734–1176)	0.83 (0.54–1.52)	0.40 (0.34–0.89)	65 (56–69)	19.1	68
3	7 (6–9)	1159 (1082–1237)	0.63 (0.5–0.79)	0.50 (0.28–0.67)	59 (56–67)	23.2	30
4	2.7 (1.5–4.8)	682 (430–1034)	0.42 (0.26–0.58)	0.23 (0.19–0.31)	71 (62–78)	13.6	20

All values are given as median.
*Unbound (=free) nilotinib concentration calculated by using published nilotinib protein binding of 98%.